Business
Jaguar Health Reports 2022 Financial Results - Prescription Revenues up 179% to $11.9 Million
Prescription product net revenue was approximately $11.9 million for the year ended December 31, 2022 versus approximately $4.3 million for the year ended
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Prescription product net revenue was approximately $11.9 million for the year ended December 31, 2022 versus approximately $4.3 million for the year ended December 31, 2021, an increase of 178.7%.Prescription product net revenue of approximately $3.3 million in Q4 2022 increased 3.4% over Q3 2022 and increased approximately 57% over prescription product net revenue in Q4 2021.As of March 24, 2023, the filing date of Jaguar's annual report on Form 10-K for the year 2022, the Company's cash position was approximately $15.3 million.Core initiatives:Patient enrollment in OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) is now at approximately 80% and expected to complete in Q2 2023.Jaguar planning to support investigator-initiated proof-of-concept (POC) studies of crofelemer in 2023 for short bowel syndrome (SBS) with intestinal failure and congenital diarrheal disorders (CDD). POC targeted for 2H 2023 in support of potential early patient access in Europe, potentially in 2024.The Company plans to submit an Investigational New Drug (IND) application in Q2 2023 to FDA for crofelemer for microvillus inclusion disease, a rare CDD condition, for which Orphan Drug Designation has been granted by both the FDA and European Medicines Agency.REMINDER: Jaguar to host investor webcast Monday, March 27th at 8:00 a.m. Eastern regarding 2022 financials and company updates; Click here to register for webcast.SAN FRANCISCO, CA / ACCESSWIRE / March 27, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\" or the \"Company\") today provided Company updates and reported consolidated financial results for the year ended December 31, 2022.The combined net revenue for Mytesi® and the Company's other crofelemer prescription product, Canalevia®-CA1, which became commercially available in April 2022, was approximately $11.9 million in the year 2022, representing an increase of 178.7% over the combined net revenue in the year 2021, which totaled $4.3 million. The combined net revenue for Mytesi and Canalevia-CA1 was approximately $3.3 million in the fourth quarter of 2022, representing an increase of 3.4% over prescription product net revenue in the third quarter of 2022, which totaled approximately $3.1 million, and an increase of approximately 57.0% over prescription product net revenue in the fourth qua...